Lanxess invested $10m at $28.49 per share as part of BioAmber's $30m series C round.
BioAmber, a Canada-based converter of feedstocks into chemicals, plans to sell eight million shares at between $15 and $17 each in its flotation on the New York Stock Exchange.
The planned price for BioAmber’s initial public offering is nearly half the value per share paid by strategic investor Lanxess in a private placement last year, according to the company’s regulatory filing.
Lanxess invested $10m at $28.49 per share as part of BioAmber’s $30m series C round.
Other investors in…
